312 related articles for article (PubMed ID: 35493490)
1. Immunovirotherapy for Pediatric Solid Tumors: A Promising Treatment That is Becoming a Reality.
de la Nava D; Selvi KM; Alonso MM
Front Immunol; 2022; 13():866892. PubMed ID: 35493490
[TBL] [Abstract][Full Text] [Related]
2. Clinical advances in oncolytic virotherapy for pediatric brain tumors.
Ghajar-Rahimi G; Kang KD; Totsch SK; Gary S; Rocco A; Blitz S; Kachurak K; Chambers MR; Li R; Beierle EA; Bag A; Johnston JM; Markert JM; Bernstock JD; Friedman GK
Pharmacol Ther; 2022 Nov; 239():108193. PubMed ID: 35487285
[TBL] [Abstract][Full Text] [Related]
3. Design and Rationale for First-in-Human Phase 1 Immunovirotherapy Clinical Trial of Oncolytic HSV G207 to Treat Malignant Pediatric Cerebellar Brain Tumors.
Bernstock JD; Bag AK; Fiveash J; Kachurak K; Elsayed G; Chagoya G; Gessler F; Valdes PA; Madan-Swain A; Whitley R; Markert JM; Gillespie GY; Johnston JM; Friedman GK
Hum Gene Ther; 2020 Oct; 31(19-20):1132-1139. PubMed ID: 32657154
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic viruses as treatment for adult and pediatric high-grade gliomas: On the way to clinical success.
Hervás-Corpión I; Alonso MM
Int Rev Cell Mol Biol; 2023; 379():169-188. PubMed ID: 37541723
[TBL] [Abstract][Full Text] [Related]
5. Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.
Jafari M; Kadkhodazadeh M; Shapourabadi MB; Goradel NH; Shokrgozar MA; Arashkia A; Abdoli S; Sharifzadeh Z
Front Immunol; 2022; 13():1012806. PubMed ID: 36311790
[TBL] [Abstract][Full Text] [Related]
6. Engineering and combining oncolytic measles virus for cancer therapy.
Leber MF; Neault S; Jirovec E; Barkley R; Said A; Bell JC; Ungerechts G
Cytokine Growth Factor Rev; 2020 Dec; 56():39-48. PubMed ID: 32718830
[TBL] [Abstract][Full Text] [Related]
7. Progress of oncolytic viruses in sarcomas.
Lettieri CK; Hingorani P; Kolb EA
Expert Rev Anticancer Ther; 2012 Feb; 12(2):229-42. PubMed ID: 22316371
[TBL] [Abstract][Full Text] [Related]
8. The Current Landscape of Oncolytic Herpes Simplex Viruses as Novel Therapies for Brain Malignancies.
Bernstock JD; Hoffman SE; Chen JA; Gupta S; Kappel AD; Smith TR; Chiocca EA
Viruses; 2021 Jun; 13(6):. PubMed ID: 34204248
[TBL] [Abstract][Full Text] [Related]
9. In Situ Cancer Vaccination and Immunovirotherapy Using Oncolytic HSV.
Jahan N; Ghouse SM; Martuza RL; Rabkin SD
Viruses; 2021 Aug; 13(9):. PubMed ID: 34578321
[TBL] [Abstract][Full Text] [Related]
10. Intraventricular immunovirotherapy; a translational step forward.
Bernstock JD; Blitz S; Kang KD; Friedman GK
Oncotarget; 2023 Jan; 14():40-43. PubMed ID: 36634220
[TBL] [Abstract][Full Text] [Related]
11. Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review.
Li M; Zhang M; Ye Q; Liu Y; Qian W
Cancer Biol Med; 2023 Aug; 20(9):646-61. PubMed ID: 37615308
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic virotherapy in lung cancer.
Nistal-Villan E; Rius-Rocabert S; Llinares-Pinel F
Int Rev Cell Mol Biol; 2023; 379():221-239. PubMed ID: 37541725
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic viruses as a promising therapeutic strategy for hematological malignancies.
Yang C; Hua N; Xie S; Wu Y; Zhu L; Wang S; Tong X
Biomed Pharmacother; 2021 Jul; 139():111573. PubMed ID: 33894623
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic Virotherapy in Glioma Tumors.
Rius-Rocabert S; García-Romero N; García A; Ayuso-Sacido A; Nistal-Villan E
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066689
[TBL] [Abstract][Full Text] [Related]
15. Arenavirus Therapy in Combination with Checkpoint Blockade as an Effective Way for Better Tumour Clearance.
Bhat H; Ali M; Hamdan TA
Cell Physiol Biochem; 2021 Nov; 55(6):726-738. PubMed ID: 34816678
[TBL] [Abstract][Full Text] [Related]
16. Immunovirotherapy for the Treatment of Glioblastoma and Other Malignant Gliomas.
Estevez-Ordonez D; Chagoya G; Salehani A; Atchley TJ; Laskay NMB; Parr MS; Elsayed GA; Mahavadi AK; Rahm SP; Friedman GK; Markert JM
Neurosurg Clin N Am; 2021 Apr; 32(2):265-281. PubMed ID: 33781507
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic Immunotherapy: Can't Start a Fire Without a Spark.
Muscolini M; Tassone E; Hiscott J
Cytokine Growth Factor Rev; 2020 Dec; 56():94-101. PubMed ID: 32826166
[TBL] [Abstract][Full Text] [Related]
18. Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory.
Martinez-Velez N; Laspidea V; Zalacain M; Labiano S; García-Moure M; Puigdelloses M; Marrodan L; Gonzalez-Huarriz M; Herrador G; de la Nava D; Ausejo-Mauleon I; Fueyo J; Gomez-Manzano C; Patiño-García A; Alonso MM
Mol Cancer Ther; 2022 Mar; 21(3):471-480. PubMed ID: 34965961
[TBL] [Abstract][Full Text] [Related]
19. Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy.
Shin DH; Nguyen T; Ozpolat B; Lang F; Alonso M; Gomez-Manzano C; Fueyo J
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795384
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potency of oncolytic virotherapy-induced cancer stem cells targeting in brain tumors, current status, and perspectives.
Bahreyni A; Ghorbani E; Fuji H; Ryzhikov M; Khazaei M; Erfani M; Avan A; Hassanian SM; Azadmanesh K
J Cell Biochem; 2019 Mar; 120(3):2766-2773. PubMed ID: 30321455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
